Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BNCT30 + SPM-011 for unresectable recurrent head and neck cancer
jRCT2080224571Phase 2Completed
- Sponsor
- Sumitomo Heavy Industries
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of boronophenylalanine in head and neck squamous cell carcinoma (HNSCC) and head and neck cancer (HNC), sponsored by Sumitomo Heavy Industries. Primary endpoint: Objective response rate at 90 days after BNCT. Started Feb 2019; status: completed.
02
Drugs
boronophenylalanine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT2080224571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224571.